» Articles » PMID: 1658748

Local Base Sequence Preferences for DNA Cleavage by Mammalian Topoisomerase II in the Presence of Amsacrine or Teniposide

Overview
Specialty Biochemistry
Date 1991 Nov 11
PMID 1658748
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Several classes of antitumor drugs are known to stabilize topoisomerase complexes in which the enzyme is covalently bound to a terminus of a DNA strand break. The DNA cleavage sites generally are different for each class of drugs. We have determined the DNA sequence locations of a large number of drug-stimulated cleavage sites of topoisomerase II, and find that the results provide a clue to the possible structure of the complexes and the origin of the drug-specific differences. Cleavage enhancements by VM-26 and amsacrine (m-AMSA), which are representative of different classes of topoisomerase II inhibitors, have strong dependence on bases directly at the sites of cleavage. The preferred bases were C at the 3' terminus for VM-26 and A at the 5' terminus for m-AMSA. Also, a region of dyad symmetry of 12 to 16 base pairs was detected about the enzyme cleavage positions. These results are consistent with those obtained with doxorubicin, although in the case of doxorubicin, cleavage requires the presence of an A at the 3' terminus of at least one the pair of breaks that constitute a double-strand cleavage (Capranico et al., Nucleic Acids Res., 1990, 18: 6611). These findings suggest that topoisomerase II inhibitors may stack with one or the other base pair flanking the enzyme cleavage sites.

Citing Articles

Debulking of topoisomerase DNA-protein crosslinks (TOP-DPC) by the proteasome, non-proteasomal and non-proteolytic pathways.

Sun Y, Saha L, Saha S, Jo U, Pommier Y DNA Repair (Amst). 2020; 94:102926.

PMID: 32674013 PMC: 9210512. DOI: 10.1016/j.dnarep.2020.102926.


Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC).

Sun Y, Saha S, Wang W, Saha L, Huang S, Pommier Y DNA Repair (Amst). 2020; 89:102837.

PMID: 32200233 PMC: 7188568. DOI: 10.1016/j.dnarep.2020.102837.


A nucleotide resolution map of Top2-linked DNA breaks in the yeast and human genome.

Gittens W, Johnson D, Allison R, Cooper T, Thomas H, Neale M Nat Commun. 2019; 10(1):4846.

PMID: 31649282 PMC: 6813358. DOI: 10.1038/s41467-019-12802-5.


Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.

Marinello J, Delcuratolo M, Capranico G Int J Mol Sci. 2018; 19(11).

PMID: 30404148 PMC: 6275052. DOI: 10.3390/ijms19113480.


Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes.

Riddell I, Agama K, Park G, Pommier Y, Lippard S ACS Chem Biol. 2016; 11(11):2996-3001.

PMID: 27648475 PMC: 5248983. DOI: 10.1021/acschembio.6b00565.


References
1.
Spitzner J, Muller M . A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res. 1988; 16(12):5533-56. PMC: 336783. DOI: 10.1093/nar/16.12.5533. View

2.
Sugiura K, Schmid F, Brown G, Gonzalez R . Chemotherapy of hamster tumors. Cancer Chemother Rep 2. 1971; 2(1):141-75. View

3.
Minford J, Pommier Y, Filipski J, Kohn K, Kerrigan D, Mattern M . Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry. 1986; 25(1):9-16. DOI: 10.1021/bi00349a002. View

4.
Pommier Y, Kerrigan D, Schwartz R, Swack J, McCurdy A . Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res. 1986; 46(6):3075-81. View

5.
Wang J . Recent studies of DNA topoisomerases. Biochim Biophys Acta. 1987; 909(1):1-9. DOI: 10.1016/0167-4781(87)90040-6. View